Our Story

Lilly Ventures has its roots in
the scientific tradition of
Eli Lilly and Company. Our
investment philosophy drives
us to seek great companies
with compelling life science innovations.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week
April 20, 2017

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

view full story

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation
April 10, 2017

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.

view full story

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel
April 6, 2017

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment

view full story

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy
April 3, 2017

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy, Prolongs Survival in Tumor Models

view full story

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102
March 29, 2017

Aeglea Biotherapeutics to Present Preclinical Data for AEB1102 at 2017 AACR Annual Meeting

view full story

Aeglea Biotherapeutics to Present Topline Data
March 23, 2017

Aeglea Biotherapeutics to Present Topline Data from Phase 1 Trial of AEB1102

view full story

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer
March 17, 2017

FORMA Therapeutics announces achievement of first clinical development milestone in partnership with Boehringer

view full story

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint
March 2, 2017

Coherus Biosciences announces CHS-1420 pharmacokinetic clinical bioequivalence study meets primary endpoint

view full story

Symic Bio Announces Last Patient Enrolled in SHIELD Trial
February 24, 2017

Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease

view full story

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson's research
February 21, 2017

FORMA Therapeutics awarded grant from the Michael J. Fox foundation for Parkinson’s research

view full story

Protagonist Therapeutics Presents Data on Oral Peptide
February 17, 2017

Protagonist Therapeutics Presents Data on Oral Peptide

view full story

Coherus prices public offering of common stock
February 8, 2017

Coherus prices public offering of common stock

view full story

Coherus Biosciences announces positive topline 24-week treatment phase three results
January 10, 2017

Coherus Biosciences announces positive topline 24-week treatment phase three results for CHS-1420 (HUMIRA® biosimilar candidate) in patients with psoriasis

view full story

Allergan Enters Parkinson’s Disease Through Option Arrangement with LTI
January 9, 2017

Allergan Enters Parkinson’s Disease Through Option Arrangement with Lysosomal Therapeutics Inc. (LTI) for its Potential First-In-Class Breakthrough Compounds

view full story

Viamet Reports Positive Results from RENOVATE
January 6, 2017

Viamet Reports Positive Results from RENOVATE Phase 2b Trial of Oral VT-1161 in Onychomycosis

view full story

Viamet Reports Positive Results from REVIVE
January 6, 2017

Viamet Reports Positive Results from REVIVE Phase 2b Trial of Oral VT-1161 in Recurrent Vulvovaginal Candidiasis

view full story

Cavion Raises $26.1 MM Series A Financing
January 6, 2017

Cavion Raises $26.1 MM Series A Financing

view full story

Nimbus Appoints Mark Ashwell, Ph.D., as Head of Chemistry
January 5, 2017

Nimbus Appoints Mark Ashwell, Ph.D., as Head of Chemistry

view full story

Surface Welcomes Daniel S. Lynch as Chairman of Board
January 4, 2017

Surface Oncology Welcomes Industry Leader Daniel S. Lynch as Chairman of Board of Directors

view full story

Innocrin Presents Data SABCS 2016 Poster
December 13, 2016

Innocrin Pharmaceuticals Presents Data SABCS 2016 Poster

view full story

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity
December 6, 2016

Sutro ADC Targeting CD74 Exhibits Potent Anti-tumor Activity

view full story

Nimbus Therapeutics announces $200M milestone
November 1, 2016

Nimbus Therapeutics announces $200 million milestone from Gilead Sciences

view full story

Innocrin Appoints Edwina Baskin-Bey MD as CMO and Expands BCa study
October 5, 2016

Innocrin Appoints Edwina Baskin-Bey MD as Chief Medical Officer and Expands BCa study

view full story